Hongxia Lin
About Hongxia Lin
Hongxia Lin is a Senior PK Scientist at Bristol Myers Squibb with extensive experience in preclinical pharmacokinetics and drug metabolism.
Title and Current Position
Hongxia Lin is a Senior Pharmacokinetic (PK) Scientist at Bristol Myers Squibb. She is currently based in Lawrence Township, New Jersey, United States. In her role, she focuses on the pharmacokinetics of drug candidates, examining how these drugs are absorbed, distributed, metabolized, and excreted in the body.
Previous Experience
Before joining Bristol Myers Squibb, Hongxia Lin worked at Boehringer Ingelheim as a Senior PK Scientist for one year from 2019 to 2020 in North Brunswick, NJ. Prior to that, she served as a PK/PD Specialist at The Cancer Institute of New Jersey for ten years, from 2008 to 2018, in New Brunswick, NJ. Her earlier roles include Research Teaching Specialist at UMDNJ from 2006 to 2008 in Newark, NJ, and Postdoctoral Associate at Seoul National University from 2005 to 2006 in Seoul, Korea.
Educational Background
Hongxia Lin earned her Ph.D. in Pharmacy from Pusan National University between 2002 and 2005. She also holds an M.S. in Pharmaceutics and a B.S. in Pharmacy, both from Shenyang Pharmaceutical University. She completed her M.S. from 1998 to 2001 and her B.S. from 1994 to 1998.
Expertise and Skills
Hongxia Lin has extensive hands-on preclinical pharmacokinetic experience in bioavailability, dose proportionality, quantitative tissue distribution, and allometric scaling in animal models. She is proficient in a variety of PK data analysis software tools, including WinNonlin. Her research experience focuses on drug metabolism and pharmacokinetics (DMPK), specifically on transporters, CYP enzymes, and proteins involved in drug metabolism and disposition.
Strengths and Collaborations
Hongxia Lin's key strengths include experimental design, data analysis, and report writing. She has a rich background in collaborative research and is experienced in working as part of a team. Her work involves extensive collaboration with interdisciplinary teams to advance drug development projects.